XT
XLO icon

XTX Topco’s Xilio Therapeutics XLO Stock Holding History

XTX Topco’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,236
Closed -$11.1K – 4467
2025
Q4 		$11.1K Sell
1,236
-4,196
-77% -$44.1K ﹤0.01% 3170
2025
Q3 		$64.1K Buy
5,432
+2,952
+119% +$29.6K ﹤0.01% 2118
2025
Q2 		$23.6K Buy
+2,480
New +$26.2K ﹤0.01% 2140
2025
Q1 		– Sell
-919
Closed -$12.3K – 3207
2024
Q4 		$12.3K Sell
919
-785
-46% -$10.8K ﹤0.01% 2119
2024
Q3 		$18.8K Sell
1,704
-674
-28% -$8.27K ﹤0.01% 1861
2024
Q2 		$31.5K Buy
+2,378
New +$37.2K ﹤0.01% 1562

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco's XLO Position: Q1 2026 in Review

XTX Topco sold out of Xilio Therapeutics (XLO) in Q1 2026, closing a stake of 1,236 shares — an estimated $11.1K sold.

XTX Topco first reported a position in XLO in Q2 2024 and held it in 6 quarters. The position peaked at $64.1K in Q3 2025. 24 funds tracked by Wall St. Rank hold XLO as of Q1 2026.

  • XTX Topco reported no remaining Xilio Therapeutics position as of Q1 2026 after selling out during the quarter.
  • XTX Topco sold 1,236 Xilio Therapeutics shares in Q1 2026, an estimated $11.1K.
  • XTX Topco first reported a position in Xilio Therapeutics in Q2 2024 and held it in 6 quarters.
  • XTX Topco's Xilio Therapeutics position peaked at $64.1K in Q3 2025.
  • 24 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.